Drug Safety

From time to time, the CSEM receives notices about drug safety issuees from Health Canada.

Current notices:

  • Methadone Summary Safety Review (SSR): Health Canada assessing potential risk of hypoglycemia (February 8, 2022)
  • Lupron and Lupron Depot: Risk of pseudotumor cerebri/idiopathic intracranial hypertension in pediatric patients (January 4, 2022)
  • One lot of Eli Lilly Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022) recalled (September 25, 2021):
  • Dopamine agonist withdrawal syndrome (June 7, 2021):